ATE331800T1 - Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor - Google Patents

Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor

Info

Publication number
ATE331800T1
ATE331800T1 AT98924964T AT98924964T ATE331800T1 AT E331800 T1 ATE331800 T1 AT E331800T1 AT 98924964 T AT98924964 T AT 98924964T AT 98924964 T AT98924964 T AT 98924964T AT E331800 T1 ATE331800 T1 AT E331800T1
Authority
AT
Austria
Prior art keywords
repressor
transcription
regulation
viral replication
tetracycline repressor
Prior art date
Application number
AT98924964T
Other languages
English (en)
Inventor
Feng Yao
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE331800T1 publication Critical patent/ATE331800T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98924964T 1997-06-26 1998-05-29 Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor ATE331800T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/883,327 US5972650A (en) 1997-06-26 1997-06-26 Tetracycline repressor regulated mammalian cell transcription and viral replication switch

Publications (1)

Publication Number Publication Date
ATE331800T1 true ATE331800T1 (de) 2006-07-15

Family

ID=25382404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924964T ATE331800T1 (de) 1997-06-26 1998-05-29 Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor

Country Status (7)

Country Link
US (3) US5972650A (de)
EP (1) EP0990041B1 (de)
JP (3) JP3577323B2 (de)
AT (1) ATE331800T1 (de)
CA (1) CA2293612C (de)
DE (1) DE69835085T2 (de)
WO (1) WO1999000510A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
WO2000006751A2 (en) * 1998-07-30 2000-02-10 Advec Inc. Repressor proteins producing cell lines for the propagation of vectors
CA2353800A1 (en) * 1998-12-02 2000-06-08 Trustees Of Boston University Gene networks for control of gene expression
JP2003506047A (ja) * 1999-07-30 2003-02-18 ユニバーシティ カレッジ ロンドン マイクロカプセル封入した酸化窒素シンターゼ源
EP1083230A1 (de) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
AU2001288682A1 (en) 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
WO2002020811A2 (en) * 2000-09-09 2002-03-14 Basf Plant Science Gmbh Modified tet-inducible system for regulation of gene expression in plants
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
CA2437201C (en) * 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
GB0106786D0 (en) * 2001-03-19 2001-05-09 Gendaq Ltd Gene regulation
AU2002257420A1 (en) * 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2003012054A2 (en) 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
WO2003022311A1 (en) * 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
CN1606456A (zh) 2001-10-02 2005-04-13 克雷顿研究院 限制性表达慢病毒载体
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
EP1531666B1 (de) * 2002-05-29 2013-10-23 Regeneron Pharmaceuticals, Inc. Induzierbares eukaryonten-expressionssystem
JP2006522582A (ja) * 2002-09-05 2006-10-05 インヴィトロジェン コーポレーション 核酸を合成するための組成物および方法
US20050071893A1 (en) * 2002-10-17 2005-03-31 Jost Seibler SiRNA mediated gene silencing in transgenic animals
CN1759182A (zh) * 2002-11-22 2006-04-12 克雷顿研究院 调节基因的组合物和系统
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US9273326B2 (en) * 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
DE602005027738D1 (de) * 2004-11-18 2011-06-09 Univ Hiroshima Nat Univ Corp Verfahren und kit zur expression von protein unter regulation der expression von einer durch genamplifikation gebildeten wiederholungssequenz und transformant
WO2007073513A2 (en) * 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
EP2049686A4 (de) * 2006-08-10 2010-02-17 Univ Leland Stanford Junior Differentielle zellmarkierung
DE602008004476D1 (de) * 2007-03-09 2011-02-24 Vectorlogics Inc Zellen für adenovirusvektor- und proteinherstellung
US8645115B2 (en) 2008-12-22 2014-02-04 Trustees Of Boston University Modular nucleic acid-based circuits for counters, binary operations, memory and logic
US8796440B2 (en) 2009-08-31 2014-08-05 The Brigham And Women's Hospital, Inc. Promote system for regulatable gene expression in mammalian cells
US8809047B2 (en) * 2009-12-21 2014-08-19 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
EP2596128B1 (de) 2010-07-22 2015-04-22 President and Fellows of Harvard College Biologische klassierschaltungen mit mehrfacheingabe für zellen
EP2710130B1 (de) 2011-05-19 2022-06-29 Fundación Pública Andaluza Progreso Y Salud Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren
WO2013155439A1 (en) 2012-04-13 2013-10-17 Massachusetts Institute Of Technology Analog and mixed-signal computation and circuits in living cells
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
JP6430481B2 (ja) 2013-03-13 2018-11-28 トラスティーズ オブ ボストン ユニバーシティ 合成および内因性の細菌システムにおけるタンパク質分解の調整可能な制御
JP6525951B2 (ja) 2013-03-14 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アペリン融合タンパク質およびその使用
KR102358807B1 (ko) 2013-10-11 2022-02-08 리제너론 파마슈티칼스 인코포레이티드 대사적으로 최적화된 세포 배양
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
JP6325751B2 (ja) 2014-11-04 2018-05-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１６ワクチン
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
WO2017059245A2 (en) 2015-09-30 2017-04-06 Trustees Of Boston University Deadman and passcode microbial kill switches
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
JP6937309B2 (ja) * 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
US20200317738A1 (en) 2016-05-26 2020-10-08 University College Cork - National University Of Ireland, Cork Methods for increasing proliferation of mammalian cells
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
EP3673044A1 (de) 2017-08-25 2020-07-01 University College Cork-National University of Ireland, Cork Bifidobacterium longum zur behandlung von adipositas und gewichtskontrolle
US20200345051A1 (en) 2017-11-24 2020-11-05 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
WO2020006409A1 (en) 2018-06-28 2020-01-02 Trustees Of Boston University Systems and methods for control of gene expression
EP3604507A1 (de) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork Omega-transaminase-enzym
EP3783012A1 (de) 2019-08-20 2021-02-24 Nuritas Limited Antimikrobielles peptid
JP2022545265A (ja) 2019-08-20 2022-10-26 ニューリタス リミテッド 筋萎縮を治療するためのペプチド
CN114980913B (zh) 2019-10-22 2025-09-30 努里塔斯有限公司 非酒精性脂肪性肝病的治疗
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
EP4070670A1 (de) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 und verwendungen davon
JP2024514194A (ja) 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 変形性関節症の治療に使用するためのｐｓｇ１
AU2022259536A1 (en) 2021-04-14 2023-11-09 University College Cork - National University Of Ireland, Cork Treatment of cerebrovascular events and neurological disorders
CN120379687A (zh) 2022-10-14 2025-07-25 爱尔兰国立科克大学 胎盘表达的蛋白用于治疗肌腱损伤
WO2025133189A1 (en) 2023-12-20 2025-06-26 Nuritas Limited Sleep promoting peptides and the use thereof
WO2025133254A2 (en) 2023-12-20 2025-06-26 Nuritas Limited Angiotensin-converting enzyme (ace) inhibiting peptides.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE165397T1 (de) * 1991-06-27 1998-05-15 Genelabs Tech Inc Screeningtest für den nachweis von dna-bindenden molekülen
WO1993001301A1 (en) * 1991-07-05 1993-01-21 The Penn State Research Foundation Mutant antiviral regulatory proteins
US5917122A (en) * 1992-08-26 1999-06-29 Byrne; Guerard Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic mice
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5965440A (en) * 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch

Also Published As

Publication number Publication date
CA2293612A1 (en) 1999-01-07
WO1999000510A1 (en) 1999-01-07
JP2000515769A (ja) 2000-11-28
US6251640B1 (en) 2001-06-26
JP3577323B2 (ja) 2004-10-13
JP3769573B2 (ja) 2006-04-26
JP2005053932A (ja) 2005-03-03
JP2004222733A (ja) 2004-08-12
CA2293612C (en) 2007-05-08
EP0990041A1 (de) 2000-04-05
JP3638279B2 (ja) 2005-04-13
DE69835085T2 (de) 2007-01-18
US6444871B1 (en) 2002-09-03
EP0990041B1 (de) 2006-06-28
DE69835085D1 (de) 2006-08-10
US20020028484A1 (en) 2002-03-07
US5972650A (en) 1999-10-26

Similar Documents

Publication Publication Date Title
ATE331800T1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
EE04753B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin
Yao et al. Gene therapy in wound repair and regeneration
ATE172496T1 (de) Wirt-vektor system zur anwendung in gentherapie
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
ATE468859T1 (de) Immunogene zusammensetzung und verfahren
Razin et al. Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin
DE60030324D1 (de) Replikationsunfähige herpesviren zur verwendung in gentherapie
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
CA2447300A1 (en) Cell-specific replication-competent vector
ATE241387T1 (de) Verfahren zur in vivo dns-verabreichung durch verwendung eines nadelfreien geräts
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
Kumar et al. Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells
EP1469077A4 (de) Zellspezifischer expressions-/replikationsvektor
Petricciani The liberation of animal cells: Psychology of changing attitudes
WO2002038188A3 (de) Verwendung der humanen lrp/mvp promotors für einen therapie-induzierbaren vektor
Monroe et al. Activating transcription with light using caged DNA
Rendell SB-509

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties